Saturday 17 October 2026 Export BCYC’s income statement to Excel — free account

Bicycle Therapeutics PLC Sponsored ADR

Bicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024. In the quarter to June 2026, revenue fell 78.5%, EPS grew 36.8% and free cash flow grew 32.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

3.46 0.14 −3.89%

Follow BCYC

Alert me

Market cap: $181.4M
P/E: 0.0×
Fwd P/E: −1.8×
Dividend yield: —
F-score: 2/9
Altman Z: 0.99
Beneish M: −1.37
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.46

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	6	—	—	5	—	—	5	—	—	1

Insider Ownership 34.96%

Capital & Financial Ratios $m

Market Cap 181.37

Revenue 61.21

Net Income (190.41)

Free Cash Flow (208.28)

Net Debt (510.05)

Current Ratio 12.08

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.76)

P/S ratio 3.95

P/B ratio 0.47

Past 5Y EPS Growth —

This Y EPS Growth 23.13%

Next Y EPS Growth 4.49%

Next Y revenue growth (75.85%)

Next 5Y EPS Growth 6.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.50%

10-year low 10-year high

P/B against its own 10 years 0.22%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	526	880	628	510
Receivables	24	36	36	47
Inventory	—	—	—	—
Other	—	—	—	—
	562	929	683	575

	2023	2024	2025	Q'26
Payables	13	16	10	6
ST’ Debt	—	—	—	—
Other	—	—	—	—
	70	67	57	48

Compound Annual Growth %

	10y	5y	3y
Sales	—	47.52%	71.21%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	44.91%	31.09%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	10	3	12	48	73
’24	20	9	3	4	35
’23	5	11	5	5	27
’22	4	4	3	3	14
’21	2	2	4	4	12
’20	1	2	4	4	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(66)	(50)	—	—	—
’25	(86)	(73)	(71)	(19)	(250)
’24	(71)	(45)	(40)	(9)	(165)
’23	(46)	34	(1)	(47)	(61)
’22	(26)	(24)	(6)	(30)	(86)
’21	(14)	(12)	22	(10)	(15)
’20	21	(12)	(10)	(17)	(18)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(67)	(50)	—	—	—
’25	(87)	(73)	(72)	(20)	(252)
’24	(71)	(45)	(40)	(10)	(166)
’23	(49)	34	(2)	(47)	(64)
’22	(31)	(33)	(9)	(32)	(105)
’21	(14)	(13)	22	(12)	(17)
’20	21	(13)	(10)	(17)	(19)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.87)	(0.72)	—	—	—
’25	(0.88)	(1.14)	(0.85)	(0.29)	(3.16)
’24	(0.62)	(0.77)	(0.74)	(0.75)	(2.90)
’23	(1.30)	(1.41)	(1.26)	(1.16)	(5.08)
’22	(0.93)	(0.90)	(0.96)	(1.01)	(3.80)
’21	(0.73)	(0.74)	(0.59)	(0.63)	(2.67)
’20	(0.63)	(0.67)	(0.52)	(0.83)	(2.66)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	6.24	9.16	18.00	12.08	12.54	12.17	6.03	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	14.91	22.71	62.08	60.80	31.91	28.67	15.47
People
People	Employees	—	—	61	72	87	119	236	284	305	288
	Revenue/emp, $m	—	0.00	0.12	0.19	0.12	0.10	0.06	0.09	0.12	0.25
Income, $m
Income, $m	Revenue	—	2	7	14	10	12	14	27	35	73
	Gross margin, %	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(14)	(16)	(22)	(31)	(52)	(68)	(114)	(179)	(174)	(219)
	EBT margin, %	0.00	(790.39)	(311.69)	(223.62)	(497.92)	(585.47)	(789.88)	(664.32)	(492.69)	(301.45)
	Net income	(14)	(16)	(22)	(31)	(51)	(67)	(113)	(181)	(169)	(219)
	Depreciation	0	0	1	1	1	1	4	7	7	6
Per share, $
Per share, $	Revenue	0.00	6.18	16.26	1.25	0.54	0.47	0.49	0.76	0.61	1.05
	Earnings	(0.76)	(48.81)	(49.78)	(2.77)	(2.66)	(2.67)	(3.80)	(5.08)	(2.90)	(3.16)
	Cash flow	(0.54)	(4.25)	(59.42)	(2.59)	(0.93)	(0.59)	(2.90)	(1.70)	(2.83)	(3.60)
	Capex	0.00	(3.34)	(2.70)	(0.14)	(0.06)	(0.08)	(0.64)	(0.08)	(0.02)	(0.03)
	Free cash flow	(0.54)	(7.59)	(62.12)	(2.73)	(0.99)	(0.67)	(3.54)	(1.79)	(2.85)	(3.64)
	Book value	0.38	(141.65)	(159.09)	8.44	4.99	13.82	9.13	10.42	13.62	8.80
	Shares, m	21	0	0	11	19	25	30	36	58	69
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.93	0.93	7.55	33.08	130.42	61.52	24.33	23.10	6.76
	P/B	—	0.00	0.00	1.12	3.60	4.41	3.29	1.77	1.03	0.80
	EV/Sales	—	(4.61)	(4.61)	1.01	21.47	95.67	40.39	6.13	(1.30)	(1.61)
	EV/FCF	—	1.95	1.95	(0.46)	(11.75)	(66.52)	(5.56)	(2.60)	0.28	0.46
Cash, $m
Cash, $m	Operating cash flow	(11)	(1)	(26)	(29)	(18)	(15)	(86)	(61)	(165)	(250)
	Capex	0	(1)	(1)	(2)	(1)	(2)	(19)	(3)	(1)	(2)
	Free cash flow	(11)	(3)	(27)	(30)	(19)	(17)	(105)	(64)	(166)	(252)
Balance, $m
Balance, $m	Working capital	7	62	68	95	133	422	316	492	861	626
	Total debt	—	—	—	1	15	30	30	31	—	—
	Net debt	(9)	(68)	(63)	(91)	(121)	(409)	(309)	(496)	(880)	(628)
	Shareholders’ equity	8	(47)	(70)	93	95	346	271	371	793	610
Returns, %
Returns, %	ROA	(31.48)	(37.88)	(28.07)	(31.91)	(37.60)	(20.85)	(25.32)	(35.92)	(21.78)	(26.15)
	ROIC	0.00	0.00	0.00	(704.84)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	33.37	40.16	37.34	(261.92)	(54.08)	(30.25)	(36.53)	(56.31)	(29.04)	(31.21)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
YARW Yarrow Bioscience, Inc	$188.8M	— (loss-making)	— (loss-making)	+40.58% (above 0%: growing)	n/m	+81.56% (above 0%: growing)	100.00%	(3,197.94%)	Compare
TRDA Entrada Therapeutics, Inc.	$186.1M	— (loss-making)	— (loss-making)	−53.95% (below 0%: shrinking)	n/m	−9.10% (below 0%: shrinking)	100.00%	(5,007.02%)	Compare
UPB Upstream Bio, Inc.	$184.6M	— (loss-making)	— (loss-making)	−17.50% (below 0%: shrinking)	n/m	+9.33% (above 0%: growing)	100.00%	(5,480.98%)	Compare
ELDN Eledon Pharmaceuticals, Inc.	$184.5M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%	Compare
SION Sionna Therapeutics, Inc.	$184.5M	— (loss-making)	—	—	n/m	−22.40% (below 0%: shrinking)	—	0.00%	Compare
ACOG Alpha Cognition Inc.	$184.0M	— (loss-making)	—	+267.56% (above 0%: growing)	n/m	−109.25% (below 0%: shrinking)	94.80%	(127.29%)	Compare
BCYC Bicycle Therapeutics PLC Sponsored ADR	$181.4M	— (loss-making)	— (loss-making)	−78.46% (below 0%: shrinking)	n/m	+31.95% (above 0%: growing)	100.00%	(8,673.93%)
PEPG PepGen, Inc.	$175.2M	— (loss-making)	—	—	n/m	+33.02% (above 0%: growing)	0.00%	0.00%	Compare
ORMP Oramed Pharmaceuticals Inc.	$173.9M	1.0×	— (loss-making)	+193.26% (above 0%: growing)	+493.75% (above 0%: growing)	+94.29% (above 0%: growing)	0.65%	0.00%	Compare
Median of peers	$184.5M	—	—	+40.58%	—	+0.11%	94.80%	(63.64%)

All 614 Biotechnology stocks →

Bicycle Therapeutics PLC Sponsored ADR (BCYC) key facts

Strength: Bicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, BCYC traded at $3.46, a market capitalization of $181.4 million.
Return on equity was −31.2% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.99 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.